Who are the top shareholders of the Vista Pharma.?

The top shareholders of Vista Pharma include Murali Meraga with 14.62%, Vista Pharmaceuticals Inc. with 10.69%, and individual investors holding 33.62%. There are no foreign institutional investors or pledged promoter holdings.

The top shareholders of Vista Pharma include Vista Pharmaceuticals Inc., which holds 10.69%, and Murali Meraga, who is the highest public shareholder with 14.62%. Additionally, individual investors collectively hold 33.62% of the shares. There are also four mutual fund schemes with a minor holding of 0.02%, but no foreign institutional investors are involved. Notably, there are no pledged promoter holdings in the company.

how big is Vista Pharma.?

As of October 2023, Vista Pharmaceuticals Ltd has a market capitalization of 44.00 Cr, classifying it as a Micro Cap company, with recent net sales of 10.08 Cr and a net profit of -4.65 Cr over the last four quarters. Shareholder's funds are reported at 40.46 Cr, with total assets of 54.67 Cr as of March 2024.

Market Cap: Vista Pharmaceuticals Ltd has a market capitalization of 44.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes data from Mar'25, Dec'24, Sep'24, and Jun'24, is 10.08 Cr. The sum of Net Profit for the same quarters is -4.65 Cr. This data is presented on a Standalone basis.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 40.46 Cr, and the Total Assets amount to 54.67 Cr.

Who are in the management team of Vista Pharma.?

As of March 2022, the management team of Vista Pharma includes Dhananjaya Alli (Chairman), Murali Meraga (Managing Director), and several directors, both executive and non-executive, contributing to the company's governance and operations.

As of March 2022, the management team of Vista Pharma includes the following individuals:<BR><BR>1. Dhananjaya Alli - Chairman & Wholetime Director<BR>2. Murali Meraga - Managing Director<BR>3. Pavan Sathvik Gilaka - Whole Time Director (Operations)<BR>4. Umakanth Katta - Director<BR>5. Divakar Reddy Yerrabommanahalli - Director<BR>6. G Narendra - Non-Executive & Independent Director<BR>7. M H Rao - Non-Executive & Non-Independent Director<BR>8. Stanley Prabhakar Reddy - Non-Executive & Non-Independent Director<BR>9. Umesh V Banakar - Non-Executive & Independent Director<BR>10. Chakravarthula Divya Bhavani - Non-Executive & Independent Director<BR><BR>This team comprises a mix of executive and non-executive directors, contributing to the governance and operational management of the company.

What does Vista Pharma. do?

Vista Pharmaceuticals Ltd formulates pharmaceutical products in the micro-cap market. As of March 2025, it reported net sales of 3 Cr and a net loss of 2 Cr, with a market cap of Rs 44 Cr.

Overview: <BR>Vista Pharmaceuticals Ltd is engaged in the formulation of pharmaceutical products within the Pharmaceuticals & Biotechnology industry and operates in the micro-cap market segment.<BR><BR>History: <BR>Vista Pharmaceuticals Limited was incorporated on January 25, 1991, and obtained its Certificate of Commencement of Business on February 7, 1991. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 3 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -2 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 44 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.22 <BR>Return on Equity: -13.04% <BR>Price to Book: 1.19<BR><BR>Contact Details: <BR>Address: Plot No 10to14 16to20 APIIC, Industrial Estate Chotyal Nalgonda Telangana <BR>Tel: 91-09291015956 <BR>Email: admin.hyd@vistapharmaceuticals.com <BR>Website: http://www.vistapharmaceuticals.com

Has Vista Pharma. declared dividend?

No Dividend History Available

Who are the peers of the Vista Pharma.?

Vista Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Guj. Terce Labs, ANG Lifesciences, Shree Ganesh Bio, and Vilin Bio Med. Among these, Sun Pharma and Dr Reddy's Labs show excellent management and growth, while Vista Pharma has below-average ratings in management risk, growth, and capital structure, with a 1-year return of -23.81%.

Peers: The peers of Vista Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Guj. Terce Labs., ANG Lifesciences, Shree Ganesh Bio, and Vilin Bio Med.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Below Average management risk is found at Vista Pharma., Guj. Terce Labs., ANG Lifesciences, Shree Ganesh Bio, and Vilin Bio Med. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted for Vista Pharma., Divi's Lab., Torrent Pharma, Guj. Terce Labs., ANG Lifesciences, Shree Ganesh Bio, and Vilin Bio Med. Excellent capital structure is seen at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Below Average capital structure is present at Vista Pharma., Guj. Terce Labs., ANG Lifesciences, and Vilin Bio Med, with Shree Ganesh Bio having a Good capital structure.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while ANG Lifesciences has the lowest at -44.35%. Vista Pharma.'s 1-year return is -23.81%, which is significantly lower than both of these peers. Additionally, Guj. Terce Labs., ANG Lifesciences, and Shree Ganesh Bio all have negative six-month returns.

Is Vista Pharma. overvalued or undervalued?

As of April 25, 2023, Vista Pharma is considered risky and overvalued, with a PE ratio of -9.58 and an EV to EBITDA of -13.00%, significantly underperforming its peers and the Sensex.

As of 25 April 2023, Vista Pharma's valuation grade has moved from does not qualify to risky, indicating a significant shift in its perceived investment quality. The company is currently assessed as overvalued, with a PE ratio of -9.58, an EV to EBITDA of -13.00, and a ROCE of -15.40%. These ratios suggest that the company is struggling financially compared to its peers.<BR><BR>In comparison to its industry peers, Vista Pharma's valuation stands out unfavorably. For instance, Sun Pharma has a PE ratio of 35.25, while Cipla is valued attractively with a PE of 22.99. The stark contrast in these ratios highlights Vista Pharma's challenges in generating positive earnings and returns. Additionally, the company's stock has underperformed against the Sensex over the past year, with a decline of 19.86% compared to the Sensex's gain of 7.60%, further reinforcing the notion that Vista Pharma is currently overvalued.

What is the technical trend for Vista Pharma.?

As of June 5, 2025, Vista Pharma's trend is mildly bearish due to daily moving averages and weekly RSI indicating bearish sentiment, despite some mixed signals from weekly MACD and Bollinger Bands.

As of 5 June 2025, the technical trend for Vista Pharma has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish sentiment and the weekly RSI showing bearish momentum. While the weekly MACD and KST are mildly bullish, the monthly indicators remain bearish, suggesting a lack of strong upward momentum. The Bollinger Bands on a weekly basis are bullish, but the overall monthly outlook is mildly bearish. The Dow Theory indicates a mildly bullish trend on the weekly chart, but with no clear trend on the monthly. Overall, the mixed signals across different time frames reflect a cautious outlook for Vista Pharma.

When is the next results date for Vista Pharma.?

Vista Pharma is scheduled to announce its results on August 13, 2025.

Vista Pharma is scheduled to declare its results on 13 August 2025.

Are Vista Pharma. latest results good or bad?

Vista Pharmaceuticals' latest results show a concerning 52.94% decline in net sales, although net profit improved by 14%. Overall, the mixed performance has led to a 'Strong Sell' rating from analysts, indicating cautious market sentiment.

Vista Pharmaceuticals' latest results for the quarter ending June 2025 indicate a mixed performance. On one hand, the company experienced a significant decline in net sales, with a QoQ growth of -52.94%, which is concerning. However, on a positive note, the standalone net profit showed an improvement with a QoQ growth of 14.00%, reversing a previous decline.<BR><BR>Despite the stabilization reflected in the company's financial score improving from -3 to 0, the overall outlook remains cautious. The stock has received a 'Strong Sell' rating from analysts, suggesting that there are still significant concerns regarding its future performance. <BR><BR>In summary, while there are some positive indicators, particularly in net profit, the sharp decline in sales and the cautious market sentiment suggest that the results are not entirely favorable. Stakeholders will need to keep a close eye on the company's performance in the upcoming quarters to assess its trajectory in the competitive pharmaceuticals and biotechnology sector.

How has been the historical performance of Vista Pharma.?

Vista Pharma has experienced declining financial performance, with net sales dropping from 31.07 Cr in March 2019 to 10.07 Cr in March 2025, and consistent losses reflected in negative operating profits and increasing total liabilities. The company has struggled with cash flow from operations, indicating ongoing financial challenges.

Answer:<BR>The historical performance of Vista Pharma shows a fluctuating trend in net sales and profitability over the years, with significant losses in recent periods.<BR><BR>Breakdown:<BR>Vista Pharma's net sales peaked at 31.07 Cr in March 2019 but have since declined sharply, reaching only 10.07 Cr in March 2025. The total operating income followed a similar pattern, dropping from 22.76 Cr in March 2020 to 10.07 Cr in March 2025. The company has consistently reported negative operating profits, with the operating profit margin excluding other income deteriorating from 3.96% in March 2019 to -40.02% in March 2025. Profit before tax has also remained negative, with a loss of -5.29 Cr in March 2025 compared to a profit of 1.15 Cr in March 2019. The profit after tax reflects this trend, showing a loss of -4.65 Cr in March 2025, down from a profit of 0.94 Cr in March 2019. The company's total liabilities have increased from 50.74 Cr in March 2020 to 55.92 Cr in March 2025, while total assets have also risen from 50.74 Cr to 55.92 Cr in the same period. Cash flow from operating activities has remained negative, indicating ongoing challenges in generating cash from core operations. Overall, Vista Pharma's financial performance has shown a decline in revenue and profitability, with increasing losses over the years.

Should I buy, sell or hold Vista Pharma.?

Which are the latest news on Vista Pharma.?

Why is Vista Pharma. falling/rising?

As of 03-Dec, Vista Pharmaceuticals Ltd's stock price is at 8.13, down -1.22%. The stock has significantly underperformed, with declines of -11.92% over the past week and -30.98% year-to-date, while trading below its moving averages, indicating a bearish trend.

As of 03-Dec, Vista Pharmaceuticals Ltd's stock price is falling, currently at 8.13, reflecting a change of -0.1 (-1.22%). The stock has been underperforming significantly, with a decline of -11.92% over the past week and -15.49% over the past month, contrasting sharply with the Sensex, which has shown a slight increase of +1.34% in the same timeframe. Year-to-date, the stock has decreased by -30.98%, while the Sensex has gained +8.92%. <BR><BR>Today, the stock has underperformed its sector by -1.21% and has experienced a consecutive fall for the last three days, resulting in a total decline of -8.24% during this period. Additionally, Vista Pharmaceuticals is trading below its moving averages across various timeframes, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. <BR><BR>Despite a notable increase in investor participation, with delivery volume rising by 313.7% against the 5-day average, the overall sentiment remains negative, contributing to the stock's decline.